A new direction in personalized medicine: multimodal joint prediction of hepatic encephalopathy risk post-TIPS
Lin-Feng Zhou1,2, Hao-Huan Tang1,3, Jian Shen1
1Department of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Background:
Overt hepatic encephalopathy (OHE) is a common complication after transjugular intrahepatic portosystemic shunt (TIPS), adversely affecting quality of life. This study aimed to develop a predictive model integrating manual imaging, radiomics, and clinical data to forecast OHE within 1 year post-TIPS.
Methods:
This retrospective study included 338 patients who underwent TIPS between November 2015 and January 2022, divided into training and validation sets (7:3). Feature selection was performed using Chi-square test, t-test, least absolute shrinkage and selection operator, and logistic regression. Three models were built using manual CT features (Model M), radiomics (Model R), and clinical data (Model C), respectively. A combined model (Model MRC) integrated all three. Model performance was evaluated via ROC curves, calibration plots, and decision curve analysis. The primary endpoint was OHE occurrence within 1 year post-TIPS.
Results:
Within 1 year after TIPS, 79 (33.4%) participants in the training group and 34 (33.3%) participants in validation group developed OHE. Three independent models and one combined model were established and evaluated in terms of their performance. The areas under the ROC curve of Model M, Model R, Model C, and Model MRC were 0.858 (95% CI: 0.809-0.907), 0.744 (95% CI: 0.681-0.808), 0.757 (95% CI: 0.692-0.821), and 0.902 (95% CI: 0.863-0.941), respectively. F1 scores were 0.861, 0.765, 0.797, and 0.891, respectively. Model MRC demonstrated superior performance compared to the other three models.
Conclusion:
Model MRC exhibited a considerable predictive ability for OHE within the first year after TIPS.
Related Concept Videos
Hepatic Encephalopathy
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenomics: Identification of New Drug Targets
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

